Health
China’s Sinovac reports mixed findings in early coronavirus vaccine trials – The Washington Post
Study found the vaccine candidate produced a quick immune response but lower levels of antibodies than in recovered coronavirus patients.
These early results put Sinovac on the back foot to prove its vaccine is effective in ongoing Phase 3 trials.
That is a concern, said Thomas Campbell, associate dean for clinical research at the University of Colorado, of the low antibody levels in Sinovacs Phase 2 trial. Its an important point here, in terms of comparing this vaccine to, for instance, the Moderna and Pfizer vaccines.
As the world awaits a coronavirus vaccine, some in China get early doses
Indonesia, the worlds fourth-most populous…
-
General14 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News23 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News15 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
Noosa News21 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime